The total response rate (RR) of Sintilimab combined with chemotherapy group was 64%, which was significantly higher than that of the control group, and the difference was statistically significant (p=0.01). <br><br>It is proved that PD-1 monoclonal antibody helps to improve and regulate cellular immune function, exert tumor killing effect, inhibit disease progression, and obtain satisfactory clinical benefits. However, the total effective rate is lower than that reported in the literature (64%, 70%). After analysis, this may be related to all cases involved in the study are advanced patients.
正在翻译中..